OPEN ACCESS Freely available online

Journal of Depression and Anxiety

ISSN: 2167-1044

Short Communication

The Importance of Early Intervention in Bipolar Psychosis: Identifying and Treating Symptoms in the Prodromal Phase

Jessica Lawrence*

Department of Psychiatry , Institute of Behavioural and Brain Sciences, Archer University of Health and Medical Science, Brisbane, Australia

DESCRIPTION

Our knowledge of bipolar psychosis, a severe form of bipolar disease marked by bouts of psychosis during manic or depressed periods, has been improved as a result of recent studies on the subject [1]. Hallucinations, delusions or disordered thinking are symptoms of psychosis in bipolar disorder which frequently makes it more difficult to control mood swings on its own. Due to the complexity of this dual presentation diagnosis and therapy must be done with subtle approach that takes into account both mood and psychotic symptoms. Investigations on bipolar psychosis has made significant strides in a number of important areas [2]. In order to distinguish bipolar psychosis from primary psychotic diseases such as schizophrenia, diagnostic criteria have been revised. This has allowed for more precise identification and customized therapies advanced neuroimaging methods, including functional MRI and PET scans, have clarify on anomalies in brain circuits related to mood regulation and sensory processing which has given researchers important new insights into the neurological pathways involved in bipolar psychosis [3]. Furthermore biomarkers linked to psychotic symptoms in bipolar disorder have been found through genetic and molecular investigations opening up new therapeutic options. Pharmacological interventions such as antipsychotic drugs and mood stabilizers continue to be the fundamental of controlling bipolar psychosis however in order to treat instances that are resistant to therapy current studies are examining novel targets such glutamate modulation and immune system regulation [4].

Understanding bipolar psychosis

A severe form of bipolar disease known as bipolar psychosis occurs when a person has psychotic episodes during either their manic or depressed phases. Delusions disorganized thought patterns and hallucinations are examples of psychotic symptoms that can have a major negative influence on day-to-day functioning and general wellbeing. Refinement of diagnostic criteria to better distinguish bipolar psychosis from other psychotic diseases such schizophrenia has been the subject of recent investigations. Modern neuroimaging methods, such Positron Emission Tomography (PET) and functional Magnetic Resonance Imaging (MRI), have understood the brain circuits underlying bipolar psychosis by identifying anomalies in regions controlling perception and emotion. Pharmacotherapy is enhanced by psychosocial interventions such as family-focused therapy and cognitive-behavioural therapy which encourage medication adherence enhance coping mechanisms and aid in rehabilitation [5]. Even with these developments problems with stigma delayed diagnosis and lack of access to specialist care still exist. This emphasizes the need for ongoing studies and all-surround strategies to improve outcomes for people with bipolar psychosis.

Treatment of psychosis in bipolar disease

Prospective biomarkers linked to psychosis in bipolar disease have been found through genetic and molecular research, opening the door for individualized treatment strategies. Pharmacological therapies, such as mood stabilizers and antipsychotic drugs, continue to be essential for the management of bipolar psychosis [6]. To treat cases that are resistant to treatment new studies has looked into therapeutic targets such glutamate neurotransmission and inflammatory mechanisms.

Psychosocial therapies are crucial for helping people with bipolar psychosis improving medication adherence and fostering functional recovery. Examples of these interventions are Cognitive-Behavioral Therapy (CBT) and family-focused therapy [7]. Pharmacotherapy, psychotherapy and psychosocial support used in integrated care models has demonstrated potential in lowering relapse rates and enhancing long-term results [8].

CONCLUSION

Although these developments there are still obstacles to successfully treating bipolar psychosis such as a delayed diagnosis the stigma associated with mental illness and restricted access to specialized care. Subsequent investigations will try to clarify the intricate genetic and environmental elements that lead to bipolar psychosis and create focused therapies that deal with the disorder's varied manifestations.

Correspondence to: Jessica Lawrence, Department of Psychiatry , Institute of Behavioural and Brain Sciences, Archer University of Health and Medical Science, Brisbane, Australia, Email: lawrencejessica@archer.univ.edu

Received: 27-May-2024, Manuscript No. JDA-24-32327; **Editor assigned:** 29-May-2024, PreQC No. JDA-24-32327 (PQ); **Reviewed:** 13-Jun-2024, QC No. JDA-24-32327; **Revised:** 20-Jun-2024, Manuscript No JDA-24-32327 (R); **Published:** 27-Jun-2024, DOI: 10.35248/ 2167-1044.24.13.535

Citation: Lawrence J (2024). The Importance of Early Intervention in Bipolar Psychosis: Identifying and Treating Symptoms in the Prodromal Phase. J Dep Anxiety. 13: 535.

Our knowledge of bipolar psychosis's many facets from neurological processes to therapeutic approaches has improved as a result of recent investigations. Through the integration of genetic, neuroimaging and clinical research insights, healthcare professionals can more effectively customize medicines to meet the unique needs of each patient leading to improved symptom management and quality of life. Nonetheless, more work is required to overcome obstacles to diagnosis, increase accessibility to research-backed therapies and lessen the toll that bipolar psychosis takes on patients, families and healthcare systems. Science will work toto improve outcomes and offer complete treatment for people with bipolar psychosis by collaborating on new projects and using multidisciplinary methods.

REFERENCES

1. Kafantaris V, Coletti DJ, Dicker R, Padula G, Kane JM. Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. J Am Acad Child Adolesc Psychiatry. 2001;40(12):1448-1456.
2. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561-1572.
3. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. Mol Psychiatry. 2000;5(2):142-149.
4. Prata J, Santos SG, Almeida MI, Coelho R, Barbosa MA. Bridging autism spectrum disorders and schizophrenia through inflammation and biomarkers-pre-clinical and clinical investigations. Neuroinflammation. 2017;14:1-33.
5. Sotsky SM, Glass DR, Shea MT, Pilkonis PA, Collins F, Elkin I, et al. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression collaborative research program . Focus. 2006;148(2):997-290.
6. Woo CW, Chang LJ, Lindquist MA, Wager TD. Building better biomarkers: Brain models in translational neuroimaging. Nature neuroscience. 2017;20(3):365-377.
7. Hayes SC, Hofmann SG. The third wave of cognitive behavioral therapy and the rise of process-based care. World psychiatry. 2017;16(3):245.
8. Rössler W. The stigma of mental disorders. EMBO Rep. (2016);17(9):1250–1253.